ALISO VIEJO, Calif. & SAVANNAH, Ga.–(BUSINESS WIRE)–Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists, and the pharmaceutical industry, and Health Discovery Corporation (HDC) (OTCBB: […]
Head & Neck Cancer Report Launched The first chapter of the Cancer Impact Guide includes an overall summary of the current approach to diagnosis and standard of care and profiles of companies. […]
Immix Therapies Enhance Apoptotic Activity of FDA-Approved Agents by 5X and Catalyze Total Shift in Tumor Micro-Environment Immix Biopharma, Inc., a Los Angeles-based clinical-stage biopharmeceutical company developing therapies for high unmet medical […]
Initiated by a global think tank, Klosters Institute, the objective is to create a consortium committed to fostering collaboration. Research to assessing connectivity the global cancer ecosystem and published in a Cancer […]
In 2016, Chinese companies invested more than $44B in the United States. The amount of investment has been growing steadily since 2000, increasing substantially each coming year. Over the last 16 years, […]
DelMar Pharmaceuticals (DMPI.OB) started 2013 with a revealing corporate update on January 8th. In the update, president and CEO Jeffrey Bacha outlined his goals with an exciting year ahead for the company and its employees. Mr. Bacha focused primarily on the company’s lead product candidate, VAL-083, a small molecule (chemotherapy) agent that DelMar is developing in a dose escalation trial for recurrent glioblastoma multiforme (GBM).
MicroRNA’s are very small endogenous, non-coding, oligonucleotides. They are implicated in regulating a broad range of biological processes. These are molecules which are involved in important regulation of biological processes, and the potential of using these molecules as targets for treatment is becoming ever more apparent. With increased interest from big pharma, it is now important to identify a handful of smallcap companies specializing in this field.
Vancouver-based DelMar Pharmaceuticals [DMPI] is developing new drug candidates targeting orphan cancer indications representing market opportunities in the $100s of millions in North America and potentially billions of dollars worldwide. Promising data announced in 2012 with follow ups scheduled at various healthcare conferences this year coincided with the company’s recent listing on the OTCQB, which commenced Q1-2013. OneMedRadio spoke with the Del Mar CEO about these milestones.
